Pharma Exporters Alert Over Increased Customs Delays at Nhava Sheva Port, JNCH Response Under Scrutiny.
Pharmexcil, the Pharmaceuticals Export Promotion Council of India, has initiated a critical dialogue with customs authorities regarding significant delays and procedural inefficiencies in customs clearances at the Jawaharlal Nehru Custom House (JNCH) in Nhava Sheva Port. In response to numerous complaints from exporters regarding long waiting times for the assessment and clearance of consignments, as well as issues with documentation and excessive inspections, Pharmexcil has planned a high-level meeting with customs officials on July 7, 2026. The focus will be on understanding the specific bottlenecks faced by pharmaceutical exporters, particularly concerning temperature-sensitive shipments that are essential for maintaining product integrity.
The implications of these customs-related challenges are far-reaching for both the common citizen and the markets. Delays in pharmaceutical exports can lead to supply shortages, impacting the availability of essential medicines and healthcare products at competitive prices. For exporters, prolonged clearance times can increase operational costs, which may be passed on to consumers, thereby contributing to inflationary pressures in the sector. Furthermore, the current disruptions may hinder India’s competitive position in the global pharmaceuticals market, affecting investor sentiment and business confidence.
Moving forward, it is imperative that the government and the RBI focus on streamlining customs processes to alleviate these inefficiencies. The upcoming meeting between Pharmexcil and JNCH officials should pave the way for actionable policies that reduce clearance times and enhance operational transparency. Additionally, implementing technology-driven solutions for tracking consignments and automating documentation processes may prove essential in maintaining India’s status as a leading pharmaceutical exporter. The long-term outlook hinges on robust coordination between various government agencies to foster an efficient trade environment conducive to growth in the pharmaceutical sector.
Source: The Hindu
(Expert Note: This report was independently prepared by the Wealthova Economy team.)